军事知识服务平台
靶向PLEKHA4-DDX3X轴逆转HR+/HER2-乳腺癌CDK4/6抑制剂耐药的机制研究
Targeting the PLEKHA4-DDX3X axis reverses CDK4/6 inhibitor resistance in HR+/HER2-breast cancer
摘要 背景与目的:激素受体阳性/人表皮生长因子受体2阴性(hormone receptor-positive/human epidermal growth factor receptor 2-negative,HR+/HER2-)乳腺癌约占全部乳腺癌病例的75%,内分泌治疗联合CDK4/6抑制剂是晚期患者的一线标准治疗方案,但原发性治疗耐药会大幅降低临床获益.现有耐药机制研究多聚焦于PI3K通路突变亚型,尚未系统解析内分泌治疗耐药的分子异质性,Wnt通路活化相关耐药亚型及其核心驱动分子未见完整报道,PLEKHA4在乳腺癌药物抵抗中的生物学作用尚不明确.本研究旨在基于国内大样本HR+乳腺癌临床队列,分层界定全新内分泌治疗耐药分子亚型,鉴定介导内分泌治疗、CDK4/6抑制剂双重耐药的关键基因PLEKHA4,阐明PLEKHA4-DDX3X信号轴调控耐药作用的分子机制,并依托患者来源类器官(patient-derived organoid,PDO)验证疗效预测标志物,探索可落地的耐药逆转联合干预策略.方法:纳入2009-2016年复旦大学附属肿瘤医院351例初治HR+/HER2-乳腺癌临床队列,其中95例具有完整内分泌治疗信息、随访及组学数据纳入分析,采集患者转录组数据开展无监督一致性聚类,结合生存曲线、临床病理学指标完成亚型分层.体外选用MCF-7、T47D乳腺癌细胞构建PLEKHA4稳定过表达、敲低细胞株,通过细胞计数试剂盒-8(cell counting kit-8,CCK-8)活力实验、克隆形成实验、流式细胞术细胞周期检测评估细胞对阿贝西利、瑞博西利的药物敏感性.构建雌性BALB/c裸鼠乳腺脂肪垫接种移植瘤模型,给予阿贝西利干预,观测肿瘤生长并通过免疫组织化学检测增殖相关蛋白表达.采用免疫共沉淀联合质谱、双向免疫共沉淀、免疫荧光共定位及蛋白质印迹法(Western blot)实验解析PLEKHA4下游相互作用的调控分子.收集手术新鲜肿瘤标本构建PDO,梯度CDK4/6抑制剂处理验证药物应答差异,采用免疫荧光、免疫组织化学检测PLEKHA4、DDX3X在耐药肿瘤中的表达水平.结果:基于转录组特征将内分泌治疗耐药患者分为两类独立亚型:R1亚型以高频PIK3CA突变为特征,R2亚型表现为Wnt通路显著激活、PIK3CA突变率仅21%,R2亚型的PLEKHA4表达显著上调;两组年龄、肿瘤分期、Ki-67增殖指数等常规临床指标差异无统计学意义,但无复发生存率存在显著差异(P=0.001 1).体外实验证实PLEKHA4高表达可显著降低肿瘤细胞对CDK4/6抑制剂的敏感性,加速G1/S细胞周期转换,敲低PLEKHA4可恢复药物杀伤效应;体内移植瘤模型显示,沉默PLEKHA4可显著抑制肿瘤增殖,增强阿贝西利抗肿瘤作用,同步下调pRb、Cyclin D1表达及Ki-67增殖指数.机制实验证实PLEKHA4与DDX3X在细胞质内直接结合并上调DDX3X蛋白表达.PDO及配对原发肿瘤标本验证显示,CDK4/6抑制剂耐药样本中PLEKHA4、DDX3X表达显著升高,二者可作为潜在的疗效预测标志物,靶向抑制DDX3X能否逆转肿瘤耐药尚有待进一步功能实验验证.结论:本研究基于国内临床队列原创性发现一类Wnt通路激活、PI3K低频突变的HR+/HER2-内分泌治疗耐药全新分子亚型,首次证实PLEKHA4是介导内分泌治疗药物、CDK4/6抑制剂双重耐药的核心驱动分子,完整阐明PLEKHA4-DDX3X信号轴调控细胞周期诱发治疗抵抗的全新机制.PLEKHA4可作为临床便捷疗效分层标志物,DDX3X抑制剂联合CDK4/6抑制剂是值得后续探索的潜在干预方向.本研究完善了HR+乳腺癌耐药分子分型体系,为难治性乳腺肿瘤精准个体化诊疗提供理论支撑和转化依据.
Abstract:
Background and purpose:Hormone receptor-positive/human epidermal growth factor receptor 2-negative(HR+/HER2-)breast cancer accounts for 75%of all breast malignancies.Endocrine therapy combined with CDK4/6 inhibitors serves as the standard first-line regimen for advanced patients,yet intrinsic drug resistance greatly impairs clinical benefits.Previous studies on therapeutic resistance mainly focused on the PIK3CA-mutant subtype,while the molecular heterogeneity of endocrine resistance has not been systematically analyzed.The Wnt-activated resistant subtype and its core driver genes remain largely unreported,and the biological function of PLEKHA4 in breast cancer drug resistance is unclear.Based on a large domestic HR+breast cancer clinical cohort,this study aims to define a novel molecular subtype of endocrine resistance,identify PLEKHA4 as the key gene mediating dual resistance to endocrine agents and CDK4/6 inhibitors,clarify the molecular mechanism regulated by the PLEKHA4-DDX3X signaling axis,validate predictive biomarkers via patient-derived organoid(PDO),and explore feasible combination strategies to reverse drug resistance.Methods:A clinical cohort of 351 patients with treatment-naive HR+/HER2-breast cancer enrolled between 2009 and 2016 was included,of whom 95 with complete transcriptomic data,endocrine therapy information,and follow-up data were included in the final analysis.Unsupervised consensus clustering was performed on transcriptomic data,and subtype stratification was combined with survival analysis and clinicopathological correlation analysis.In vitro,MCF-7 and T47D breast cancer cell lines with stable PLEKHA4 overexpression or knockdown were constructed.Cell counting kit-8(CCK-8)assay,colony formation assay and flow cytometry cell cycle detection were applied to evaluate cellular sensitivity to abemaciclib and ribociclib.An orthotopic mammary fat pad xenograft model in female BALB/c nude mice was established,treated with abemaciclib to observe tumor growth,and immunohistochemistry was used to detect the expression of proliferation-related proteins.Immunoprecipitation-mass spectrometry,reciprocal co-immunoprecipitation,immunofluorescence co-localization,and Western blot were conducted to analyze the downstream interacting molecules regulated by PLEKHA4.Fresh surgical tumor specimens were collected to generate PDO,which was treated with gradient concentrations of CDK4/6 inhibitors to verify differential drug response.Immunofluorescence and tissue immunohistochemistry were performed to detect the expression levels of PLEKHA4 and DDX3X in resistant tumors.Results:Endocrine-resistant patients were divided into two distinct molecular subtypes according to transcriptomic profiles.Subtype R1 was characterized by high-frequency PIK3CA mutations,while subtype R2 exhibited robust Wnt pathway activation with a low PIK3CA mutation rate of only 21%,accompanied by markedly upregulated PLEKHA4.There were no statistical differences in conventional clinicopathological indicators including age,tumor stage and Ki-67 proliferation index between the two subgroups,whereas relapse-free survival showed a significant discrepancy(P=0.001 1).In vitro experiments demonstrated that elevated PLEKHA4 significantly blunted cellular sensitivity to CDK4/6 inhibitors and accelerated G1-S cell cycle transition;PLEKHA4 knockdown restored drug cytotoxicity.In vivo xenograft models revealed that silencing PLEKHA4 markedly suppressed tumor proliferation and strengthened the anti-tumor efficacy of abemaciclib,accompanied by downregulation of pRb and Cyclin D1 expression along with the Ki-67 proliferation index.Mechanistic assays verified that PLEKHA4 directly bound to DDX3X in the cytoplasm and upregulated DDX3X protein abundance.Validation in PDO and paired primary tumor specimens showed significantly higher expression of PLEKHA4 and DDX3X in CDK4/6 inhibitor resistant samples,which could act as potential predictive biomarkers;Whether targeted inhibition of DDX3X can reverse drug resistance remains to be verified by further functional experiments.Conclusion:This study originally identified a novel Wnt-activated,low-frequency PI3K mutation molecular subtype of endocrine-resistant HR+/HER2-breast cancer based on domestic clinical cohort data.For the first time,PLEKHA4 was confirmed that as the core driver conferring dual resistance to endocrine therapy and CDK4/6 inhibitors,and fully elucidated a brand-new mechanism in which the PLEKHA4-DDX3X axis induces therapeutic resistance via modulating cell cycle progression.PLEKHA4 can serve as a convenient clinical biomarker for therapeutic stratification,and the combination of DDX3X inhibitors and CDK4/6 inhibitors is a potential intervention direction worthy of subsequent exploration.This research improves the molecular classification system of drug-resistant HR+breast cancer,and supplies theoretical support and translational evidence for precise individualized management of refractory breast tumors.
刊 名 中国癌症杂志 ISTICPKU
年,卷(期): 2026, 36(9)
分类号: R737.9
机标分类号: R737.9 R979.1 R329.2
在线出版日期: 2026年11月2日